Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > NICE’s latest consultation on hybrid closed loop
The consultation document proposes a carefully controlled implementation period of five years. Technology Appraisals are normally required to be implemented after three months without any phased prioritisation. This can lead to inequity in access by those who have the greatest need. We anticipate this phased rollout period will help those with greatest need access HCL systems soonest – just as the phased Covid vaccination programme prioritised those who needed the most protection.
The final NICE appraisal document, detailing the exact criteria of who will be eligible for hybrid closed loop is due later this year. We will monitor this closely and provide comment separately if necessary.
The decision to extend the rollout period was driven by several factors:
Clinical Capacity: The extended rollout recognises the need for sufficient clinical capacity to ensure effective training and support for both healthcare staff and patients.
Specialist Support: The complex nature of insulin pumps, glucose monitors, and HCL systems requires specialised training and support for healthcare professionals. This extended period allows for the necessary investment in the workforce to provide comprehensive guidance and assistance to patients.
Variations in Access: Variations in the provision of continuous glucose monitors and insulin pumps across different healthcare centres have been acknowledged. This phased rollout will help ensure that you have access to the same standard of technology, no matter where you live.
Healthcare Inequalities: Access to technology can impact the uptake of HCL systems. The extended rollout aims to mitigate potential healthcare inequalities and ensure that the introduction of HCL does not increase existing inequalities.
Patient Benefit: The phased rollout is not expected to adversely affect patient outcomes. The National Diabetes Audit has highlighted improvements in glycaemic control for people with type 1 diabetes, and the effective implementation of HCL systems is poised to further enhance this progress.
Targeted Implementation: The proposed extended rollout will focus where the demand is highest, starting with children, younger adults, pregnancy, existing pump users transitioning to HCL, gradually expanding to new pump users.
Procurement Process: The current variation in procurement of diabetes technology, including insulin pumps, will be addressed through the development of a new commercial framework via a formal procurement process by NHS England. This effort aims to ensure consistent access to cost-effective prices across different healthcare providers.
Advancements in type 1 technology have enabled people with the condition to live longer, healthier lives without fear, by reducing the risks of complications including heart failure, loss of limbs, kidney failure and sight loss. The roll out of HCL presents the chance for yet another significant leap in treatment progress for type 1 diabetes, with the potential to remove some of the burden and transform the lives of hundreds of thousands of people.
Speaking about the development, Rachael Chrisp, Head of Policy and Public Affairs at JDRF, commented: “This proposed extended rollout marks a step closer in our journey towards improving the lives of people with type 1 diabetes. By advocating for improved criteria and a comprehensive phased implementation, we are ensuring that HCL technology becomes accessible to those who need it the most.”
The consultation for the extended roll out period is now underway, and stakeholders from across the healthcare spectrum are invited to provide their input before the final guidance is published. With JDRF’s continued dedication and collaboration with NICE, the future holds promising prospects for everyone living with type 1 diabetes in England and Wales.
We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.
If you use the Dexcom G6 app on your Android smartphone, the newest Android 16 operating system may disrupt how the app functions.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
